What is the recommended empiric therapy for community‑acquired pneumonia, including outpatient and inpatient regimens, and how should management be adjusted for penicillin allergy, severity, and risk factors for drug‑resistant organisms?

Empiric Therapy for Community-Acquired Pneumonia

For outpatient CAP in previously healthy adults without recent antibiotic use, prescribe a macrolide (azithromycin, clarithromycin, or erythromycin) or doxycycline; for hospitalized non-ICU patients, use a β-lactam (ceftriaxone, cefotaxime, or ampicillin) plus a macrolide OR a respiratory fluoroquinolone (levofloxacin 750mg, moxifloxacin); for ICU patients, use a β-lactam plus either azithromycin or a respiratory fluoroquinolone. 1

Outpatient Management

Previously Healthy Patients (No Comorbidities)

Without recent antibiotic use within 90 days:

• First-line: Macrolide monotherapy (azithromycin, clarithromycin, or erythromycin) 1
• Alternative: Doxycycline 1

With recent antibiotic use within 90 days:

• Respiratory fluoroquinolone alone (levofloxacin 750mg, moxifloxacin, or gemifloxacin) 1
• OR Advanced macrolide plus high-dose amoxicillin (1g three times daily) 1
• OR Advanced macrolide plus amoxicillin-clavulanate (2g twice daily) 1

Patients with Comorbidities

Comorbidities include: chronic heart/lung/liver/renal disease, diabetes, alcoholism, malignancy, asplenia, immunosuppression, or antimicrobial use within 3 months 1

First-line options:

• Respiratory fluoroquinolone (levofloxacin 750mg, moxifloxacin, or gemifloxacin) 1
• OR β-lactam plus macrolide (high-dose amoxicillin or amoxicillin-clavulanate preferred; alternatives: ceftriaxone, cefpodoxime, cefuroxime 500mg twice daily) 1

Critical caveat: In regions with ≥25% high-level macrolide-resistant S. pneumoniae (MIC ≥16 mg/mL), use the combination regimens above even in previously healthy patients 1

Inpatient Non-ICU Management

Two equally effective options (strong evidence):

1. β-lactam plus macrolide 1

   • Preferred β-lactams: ceftriaxone (1-2g daily), cefotaxime (1-2g every 8 hours), or ampicillin
   • Ertapenem acceptable for patients with risk factors for gram-negative pathogens (excluding Pseudomonas)
   • Macrolide: azithromycin 500mg daily or clarithromycin 500mg twice daily
   • Doxycycline is an alternative to macrolide

2. Respiratory fluoroquinolone monotherapy 1

   • Levofloxacin 750mg daily OR moxifloxacin 400mg daily

Recent high-quality research confirms no mortality difference between these regimens, with similar clinical outcomes 2. A 2024 multicenter study of 4,685 patients showed equivalent in-hospital mortality (1.5-1.9%) across fluoroquinolone monotherapy, macrolide+β-lactam, and doxycycline+β-lactam groups 2.

ICU Management (Severe CAP)

Standard Severe CAP (No Pseudomonas Risk)

Mandatory combination therapy:

• β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS
• Azithromycin OR respiratory fluoroquinolone 1

With Pseudomonas Risk Factors

Risk factors: structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization, prior IV antibiotics within 90 days

Choose one of these regimens:

1. Antipseudomonal β-lactam (piperacillin-tazobactam 4.5g q6h, cefepime 2g q8h, imipenem 500mg q6h, or meropenem 1g q8h) PLUS ciprofloxacin 400mg q8h OR levofloxacin 750mg daily 1

2. Antipseudomonal β-lactam PLUS aminoglycoside (amikacin 15-20mg/kg q24h, gentamicin 5-7mg/kg q24h, or tobramycin 5-7mg/kg q24h) PLUS azithromycin OR respiratory fluoroquinolone 1

With CA-MRSA Risk

Add to above regimens:

• Vancomycin 15mg/kg q8-12h (target trough 15-20 mg/mL; consider loading dose 25-30mg/kg for severe illness) 1, 3
• OR Linezolid 600mg q12h 1, 3

Risk factors for CA-MRSA: IV antibiotic use within 90 days, end-stage renal disease, injection drug use, prior MRSA infection 3

Penicillin Allergy Management

Outpatient

• Respiratory fluoroquinolone monotherapy 1

Inpatient Non-ICU

• Respiratory fluoroquinolone monotherapy 1

ICU Without Pseudomonas Risk

• Respiratory fluoroquinolone with or without clindamycin 1

ICU With Pseudomonas Risk

• Aztreonam 2g q8h PLUS levofloxacin 750mg daily 1
• OR Aztreonam PLUS moxifloxacin or gatifloxacin, with or without aminoglycoside 1

Special Situations

Aspiration Pneumonia

• Amoxicillin-clavulanate OR clindamycin 4

Influenza with Bacterial Superinfection

• β-lactam OR respiratory fluoroquinolone 4
• Plus oseltamivir for influenza 1
• Target S. pneumoniae and S. aureus as most common bacterial superinfections 1

Nursing Home-Acquired Pneumonia

Treated in facility:

• Respiratory fluoroquinolone alone OR amoxicillin-clavulanate plus advanced macrolide 4

Hospitalized:

• Same as medical ward or ICU regimens above 4

Duration of Therapy

Minimum 5 days with all of the following criteria met 1:

• Afebrile for 48-72 hours
• No more than 1 sign of clinical instability
• Hemodynamically stable

Extend to 14-21 days for: Legionella, Staphylococcus aureus, gram-negative enteric bacilli, or extrapulmonary complications (meningitis, endocarditis) 1, 5, 1

IV to Oral Transition

Switch when ALL criteria met:

• Hemodynamically stable
• Clinically improving
• Able to ingest medications
• Functioning GI tract 1

Discharge immediately once stable on oral therapy—inpatient observation while receiving oral antibiotics is unnecessary 1

Critical Pitfalls to Avoid

1. Do not use macrolide monotherapy for hospitalized patients—resistance rates make this inadequate 1

2. Avoid fluoroquinolone overuse in outpatients to prevent resistance—reserve for patients with comorbidities, recent antibiotic use, or treatment failure 6

3. Do not delay first antibiotic dose—administer while still in emergency department for admitted patients 1

4. Do not use vancomycin routinely for drug-resistant S. pneumoniae—it's only indicated for proven CA-MRSA 6

5. Obtain cultures before antibiotics when possible, especially for hospitalized patients, to guide de-escalation and track resistance patterns 1

6. Consider procalcitonin for duration guidance, not for withholding initial therapy—always start empiric antibiotics regardless of procalcitonin level 3